FR11C0027I2 - Virus de l'influenza recombinants pour vaccins et traitement genetique - Google Patents

Virus de l'influenza recombinants pour vaccins et traitement genetique

Info

Publication number
FR11C0027I2
FR11C0027I2 FR11C0027C FR11C0027C FR11C0027I2 FR 11C0027 I2 FR11C0027 I2 FR 11C0027I2 FR 11C0027 C FR11C0027 C FR 11C0027C FR 11C0027 C FR11C0027 C FR 11C0027C FR 11C0027 I2 FR11C0027 I2 FR 11C0027I2
Authority
FR
France
Prior art keywords
vaccines
influenza viruses
recombinant influenza
genetic treatment
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0027C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26826080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0027(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of FR11C0027I1 publication Critical patent/FR11C0027I1/fr
Application granted granted Critical
Publication of FR11C0027I2 publication Critical patent/FR11C0027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FR11C0027C 1999-04-06 2011-07-26 Virus de l'influenza recombinants pour vaccins et traitement genetique Active FR11C0027I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12791299P 1999-04-06 1999-04-06
US13283999P 1999-05-06 1999-05-06
PCT/US2000/009021 WO2000060050A2 (en) 1999-04-06 2000-04-05 Recombinant influenza viruses for vaccines and gene therapy

Publications (2)

Publication Number Publication Date
FR11C0027I1 FR11C0027I1 (fr) 2011-08-26
FR11C0027I2 true FR11C0027I2 (fr) 2021-12-31

Family

ID=26826080

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0027C Active FR11C0027I2 (fr) 1999-04-06 2011-07-26 Virus de l'influenza recombinants pour vaccins et traitement genetique

Country Status (19)

Country Link
EP (4) EP1820853B1 (OSRAM)
JP (3) JP5543048B2 (OSRAM)
KR (1) KR100702275B1 (OSRAM)
CN (2) CN101851636B (OSRAM)
AT (2) ATE368729T1 (OSRAM)
AU (1) AU4073300A (OSRAM)
BR (1) BRPI0009580B8 (OSRAM)
CA (2) CA2928263A1 (OSRAM)
CY (2) CY1108520T1 (OSRAM)
DE (6) DE122008000035I1 (OSRAM)
DK (3) DK1185615T3 (OSRAM)
ES (3) ES2533622T3 (OSRAM)
FR (1) FR11C0027I2 (OSRAM)
HK (1) HK1214298A1 (OSRAM)
IL (2) IL145702A0 (OSRAM)
MX (1) MXPA01010082A (OSRAM)
NL (2) NL300364I2 (OSRAM)
PT (2) PT1820853E (OSRAM)
WO (1) WO2000060050A2 (OSRAM)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
ATE368729T1 (de) * 1999-04-06 2007-08-15 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
GB9916794D0 (en) * 1999-07-16 1999-09-22 Isis Innovation In vitro virus reconstitution
DE122007000070I1 (de) * 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
US6951754B2 (en) 2000-04-28 2005-10-04 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
EP1862550A1 (en) * 2000-06-23 2007-12-05 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
ES2563402T3 (es) 2002-02-13 2016-03-15 Wisconsin Alumni Research Foundation Señal para el empaquetamiento de vectores del virus de la gripe
CN103540613A (zh) 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2593082T3 (es) * 2003-05-28 2016-12-05 Wisconsin Alumni Research Foundation Virus de la gripe recombinantes a título elevado para vacunas y terapia génica
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
AU2005248375B2 (en) 2004-05-25 2010-12-16 Medimmune, Llc Influenza hemagglutinin and neuraminidase varians
US7968101B2 (en) 2004-11-19 2011-06-28 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
KR20120128162A (ko) 2004-12-08 2012-11-26 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
BRPI0518568A2 (pt) 2004-12-24 2008-11-25 Solvay Pharm Bv mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568210A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
NZ570106A (en) 2006-01-27 2012-04-27 Novartis Vaccines & Diagnostic Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US9254318B2 (en) 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US20090017444A1 (en) * 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
KR101559184B1 (ko) 2006-08-09 2015-10-13 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
AU2007330494B2 (en) 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
US8673613B2 (en) 2007-06-18 2014-03-18 Medimmune, Llc Influenza B viruses having alterations in the hemaglutinin polypeptide
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
CN101497877B (zh) * 2008-01-28 2012-09-05 河北摩百生物科技有限公司 流感全病毒减活疫苗重组体、其构建方法及应用
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
US8591914B2 (en) 2008-07-11 2013-11-26 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2329845A4 (en) 2008-08-18 2013-08-14 Kitasato Daiichi Sankyo Vaccine Co Ltd BIRD GRAPEVIRUS ANTIGEN AND BOOSTER IMMUNIZATION PROCEDURE FOR BIRD FLUID VACCINE IN COMBINATION WITH A MUCOSAL ADJUVAN WITH EFFICACY THROUGH ORAL ADMINISTRATION
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
AU2010212547B2 (en) 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
EP2396033B1 (en) 2009-02-12 2016-09-28 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20130183740A1 (en) 2010-06-02 2013-07-18 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
CN102220293B (zh) * 2011-05-26 2012-12-19 中国农业科学院上海兽医研究所 犬流感重组病毒及其制备方法和应用
EP2747778B1 (en) 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
EP2751260A2 (en) 2011-09-02 2014-07-09 Westfälische Wilhelms-Universität Münster Live attenuated influenza virus
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CN107921117B (zh) * 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
EP3320343B1 (en) 2015-07-07 2020-09-02 Seqirus UK Limited Method for quantifying immunogenic hemagglutinin
JP2018530314A (ja) * 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
EP3675834A1 (en) * 2017-08-28 2020-07-08 Wisconsin Alumini Research Foundation Nanocapsules for delivering ribonucleoproteins
JP2021500891A (ja) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス
CN107964035B (zh) * 2017-12-06 2020-07-24 中国科学院微生物研究所 一种用于流感病毒的有限复制型黏膜免疫疫苗
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5658772A (en) 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
EP0704533A1 (en) * 1994-09-30 1996-04-03 Bayer Ag An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus
AU3760495A (en) * 1994-09-30 1996-04-26 Aviron Chimeric Influenza Virus And Electroporation Method
CN1200675A (zh) * 1995-10-20 1998-12-02 耶路撒冷希伯来语大学依苏姆研究开发公司 流感疫苗
US5994526A (en) * 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
EP1035209A1 (en) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
ATE368729T1 (de) * 1999-04-06 2007-08-15 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie

Also Published As

Publication number Publication date
DK1185615T3 (da) 2007-11-05
CN101851636B (zh) 2015-11-25
CA2365526A1 (en) 2000-10-12
JP6224645B2 (ja) 2017-11-01
MXPA01010082A (es) 2002-04-24
NL300365I2 (nl) 2017-08-03
ES2290024T3 (es) 2008-02-16
IL145702A0 (en) 2002-07-25
DE122008000014I1 (de) 2011-12-01
CN1350578A (zh) 2002-05-22
AU4073300A (en) 2000-10-23
JP2015119735A (ja) 2015-07-02
CY1108520T1 (el) 2014-04-09
NL300365I1 (nl) 2009-01-05
FR11C0027I1 (fr) 2011-08-26
DK1820853T3 (da) 2011-12-19
EP2345716A1 (en) 2011-07-20
JP5543048B2 (ja) 2014-07-09
PT1820853E (pt) 2012-01-03
CN101851636A (zh) 2010-10-06
CA2928263A1 (en) 2000-10-12
DE122008000035I1 (de) 2009-05-20
BR0009580B1 (pt) 2014-11-25
EP2345716B1 (en) 2015-01-14
NL300364I1 (nl) 2009-01-05
DE122011100037I1 (de) 2012-03-22
JP2011182797A (ja) 2011-09-22
JP2003528570A (ja) 2003-09-30
WO2000060050A2 (en) 2000-10-12
CN1350578B (zh) 2010-05-12
HK1214298A1 (en) 2016-07-22
DE122008000061I1 (de) 2009-02-12
EP2910629A1 (en) 2015-08-26
EP1820853A2 (en) 2007-08-22
WO2000060050A3 (en) 2001-01-18
HK1148778A1 (zh) 2011-09-16
BR0009580A (pt) 2002-01-02
ES2373405T3 (es) 2012-02-03
ES2533622T3 (es) 2015-04-13
KR100702275B1 (ko) 2007-03-30
DE60035778D1 (de) 2007-09-13
EP1820853B1 (en) 2011-09-21
DE122008000058I1 (de) 2009-05-07
NL300364I2 (nl) 2017-08-03
BRPI0009580B8 (pt) 2021-05-25
ATE368729T1 (de) 2007-08-15
KR20010113044A (ko) 2001-12-24
EP1820853A3 (en) 2007-10-03
CA2365526C (en) 2016-07-05
EP1185615A2 (en) 2002-03-13
IL145702A (en) 2010-04-15
EP2910629B1 (en) 2018-09-19
ATE525461T1 (de) 2011-10-15
DK2345716T3 (en) 2015-02-09
PT1185615E (pt) 2007-10-04
EP1185615B1 (en) 2007-08-01
CY1112140T1 (el) 2015-11-04
DE60035778T2 (de) 2008-04-30
JP5775351B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
FR11C0027I2 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
EA200201279A1 (ru) Способы и композиции для лечения вирусного гепатита c
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
BG102712A (en) Mixture of recombinant vaccinia vectors as polyenv-vaccines against hiv
EP1383931A4 (en) NUCLEIC ACID VACCINES FOR PREVENTING A FLAVIVIRUS INFECTION
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ATE395078T1 (de) Impfstoff zur vorbeugung bzw. behandlung der hepatitis c
DE60024259D1 (de) Trennung eines humanen retrovirus
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
DK1339737T3 (da) Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
FI964784A0 (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
ATE322541T1 (de) Pestivirus mutanten und dessen enthaltende impfstoffe
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
WO2002039116A3 (en) Retrovirus isolated from humans
WO2000018430A3 (en) Live virus vaccines to protect primates from hiv-1 infection and disease
WANG et al. The pilot study on mutations of HIV-1 envelop V3 loop in AIDS patients in Shenzhen
WO2000024876A3 (en) Spumavirus isolated from humans